Skip to content
Altius – Lifestyle
Author:
Precigen, Inc
Precigen’s Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
August 25, 2026
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
July 21, 2026
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
June 15, 2026
Precigen Reports ‘Robust Uptake’ of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
April 7, 2026